最高で有効なCCDM試験問題と解答PDF CCDM問題集（最近更新された152問あります)
試験問題解答はCCDM学習ガイド
質問 # 84
Which method would best identify inaccuracies in safety data tables for an NDA?
- A. Compare counts of appropriate patients from manual CRFs to counts in table cells
- B. Review the tables to identify any values that look odd
- C. Review the line listings to identify any values that look odd
- D. Compare counts of appropriate patients from line listings of CRF data to counts in table cells
正解：D
解説：
The best method for identifying inaccuracies in safety data tables prepared for a New Drug Application (NDA) is to compare counts of appropriate patients from line listings of CRF data to the counts in table cells.
According to the GCDMP (Chapter: Data Quality Assurance and Control), line listings represent raw, patient-level data extracted directly from the clinical database, whereas summary tables are aggregated outputs used for reporting and submission. Comparing these two sources ensures data traceability and accuracy, verifying that tabulated results correctly reflect the underlying patient data.
Manual CRF checks (option A) are less efficient and error-prone, as data entry is typically already validated electronically. Simply reviewing tables or listings for "odd values" (options C and D) lacks the systematic verification necessary for regulatory data integrity.
Thus, comparing line listings to tables (option B) provides a quantitative cross-check between the database and output deliverables, a standard practice in NDA data validation and statistical quality control.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 5.2 - Validation of Tables, Listings, and Figures (TLFs) FDA Guidance for Industry: Submission of NDA Safety Data, Section on Data Verification and Accuracy ICH E6 (R2) GCP, Section 5.5.3 - Validation of Derived Data Outputs
質問 # 85
In a study conducted using paper CRFs, a discrepancy is discovered in a CRF to database QC audit. What is the reason why this discrepancy would be considered an audit finding?
- A. Discrepancy not explained by the CRF completion guidelines
- B. Discrepancy not explained by the data handling conventions
- C. Discrepancy not explained by the protocol
- D. Discrepancy not explained by the data quality control audit plan
正解：B
解説：
In a CRF-to-database quality control (QC) audit, auditors compare data recorded on the paper Case Report Form (CRF) with data entered in the electronic database. If discrepancies exist that cannot be explained by documented data handling conventions, they are classified as audit findings.
Per GCDMP (Chapter: Data Quality Assurance and Control), data handling conventions define acceptable data entry practices, transcription rules, and allowable transformations. These conventions ensure that CRF data are consistently interpreted and entered.
If a discrepancy deviates from these established rules, it indicates a process gap or error in data entry, validation, or training. Discrepancies justified by protocol design or CRF guidelines would not constitute findings.
Therefore, option C (Discrepancy not explained by the data handling conventions) correctly identifies the criterion for a true QC audit finding.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Quality Assurance and Control, Section 6.1 - Data Handling Conventions and QC Auditing ICH E6(R2) GCP, Section 5.1 - Quality Management and Documentation of Deviations FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.5 - Data Verification and Audit Findings
質問 # 86
What action should be taken regarding the clinical database when MedDRA releases a new version of its dictionary?
- A. Continue using the existing version to code.
- B. Identify an alternative dictionary.
- C. Evaluate the extent and impact of the changes.
- D. Upgrade the version immediately and recode.
正解：C
解説：
When a new version of MedDRA (Medical Dictionary for Regulatory Activities) is released, the correct action is to evaluate the extent and impact of the changes before implementation.
According to the GCDMP (Chapter: Medical Coding and Dictionaries), MedDRA updates are published twice yearly (March and September). Each release may introduce new terms, modify hierarchies, or retire old ones. Prior to adopting a new version, the Data Manager and Medical Coder must:
Assess the number and type of term changes,
Determine the potential effect on ongoing coding consistency, and
Decide whether migration to the new version is warranted mid-study or deferred until database lock.
Immediate recoding (option C) without evaluation may cause inconsistencies and require additional validation. Continuing with the existing version (option B) may be acceptable short-term but must be justified. Using an alternative dictionary (option D) is noncompliant, as MedDRA is the regulatory standard for safety reporting.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Medical Coding and Dictionaries, Section 6.3 - Version Control and Impact Assessment MedDRA Term Selection: Points to Consider (MSSO, Latest Version), Section 3 - Versioning and Maintenance ICH E2B(R3) - Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports
質問 # 87
A study has an expected enrollment period of one year but has subject recruitment issues. Twelve new sites are added toward the end of the expected enrollment period to help boost enrollment. What is the most likely impact on data flow?
- A. The distribution of subjects selected for quality control will need to be stratified to allow for the twelve new sites.
- B. A bolus of CRFs at the end of the study will result in the need to increase data entry and cleaning rates to meet existing timelines.
- C. The database set-up will need to be changed to allow for additional sites as they are added to the study.
- D. Additional sites will likely have increased query rates since site training is occurring closer to study close.
正解：B
解説：
Adding multiple new sites late in the enrollment period creates a concentrated influx of new data near the end of the study. These sites typically start enrolling patients later, resulting in a "bolus" of Case Report Forms (CRFs) that must be entered, validated, and cleaned within a shorter timeframe to meet database lock deadlines.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Project Management and Data Flow), late site activation compresses the timeline for data management tasks, necessitating increased resources for data entry, query management, and cleaning. Data management teams must anticipate this surge and plan accordingly-either by increasing staffing or revising timelines to prevent bottlenecks and maintain quality.
While option D (increased query rates) can occur, it is a secondary effect. The most direct and consistent impact is the surge in data volume requiring expedited processing near study end.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Project Management, Section 5.3 - Managing Changes in Site Activation and Data Flow ICH E6(R2) GCP, Section 5.1 - Quality Management and Oversight
質問 # 88
An astute monitor discovers that a site is using nebulized albuterol rather than the inhaler provided in the study screening kit for the albuterol challenge. Which is the best response from the Data Manager?
- A. Update the CRF Completion Guidelines and notify all sites of the update
- B. Contact the Ethics Committee
- C. Query the site to enter a Protocol Violation
- D. No response is needed, the problem does not impact data
正解：C
解説：
In this scenario, the site has deviated from the approved study protocol by using a different formulation (nebulized albuterol instead of inhaler). This is considered a protocol deviation or violation, depending on study definitions.
Per GCDMP (Chapter: Data Validation and Cleaning) and ICH E6(R2), Data Managers are responsible for ensuring that all protocol deviations affecting data integrity or subject safety are accurately captured and documented within the clinical database. The appropriate action is to issue a data query prompting the site to record the deviation in the designated section (e.g., "Protocol Deviations" CRF).
Option A: Incorrect - it affects data comparability.
Option B: Escalation to the Ethics Committee is handled by the sponsor, not the Data Manager.
Option C: Updating the CRF guidelines is premature; first, the deviation must be logged and assessed.
Therefore, option D (Query the site to enter a Protocol Violation) is the correct and compliant action.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 6.2 - Query Management and Protocol Deviations ICH E6(R2) GCP, Section 4.5 - Compliance with Protocol FDA Guidance for Industry: Oversight of Clinical Investigations - Compliance and Protocol Deviation Reporting
質問 # 89
Which database table structure is most appropriate for vital signs data collected at every-other visit for each patient in a study?
- A. One record per visit
- B. One record per patient per visit
- C. One record per patient
- D. One record per patient per study
正解：B
解説：
In a relational clinical database, the most efficient and normalized structure for data collected repeatedly over time-such as vital signs-is one record per patient per visit.
Each patient will have multiple records, one for each visit when vital signs are assessed. This structure supports:
Time-based analysis (e.g., trends across visits),
Accurate data linkage with visit-level metadata, and
Efficient querying for longitudinal data.
According to the GCDMP (Chapter: Database Design and Build), the relational design principle dictates that data should be stored at the lowest unique level of observation. Since vital signs vary by both patient and visit, the combination of patient ID + visit ID forms a unique key for each record.
Option A (per visit) lacks patient identification, while options B and D aggregate data too broadly, losing temporal detail.
Thus, option C (One record per patient per visit) correctly represents the normalized design structure.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 4.2 - Normalization and Table Structure CDISC SDTM Implementation Guide, Section 5.3 - Visit-Level and Observation-Level Data Structures ICH E6(R2) GCP, Section 5.5.3 - Data Handling Principles
質問 # 90
A study team member states that data entry can be done by clerical personnel at sites. Which are important considerations?
- A. The person at the sites who enters the data usually also understands which data in the medical record are needed for the study, where to find them and which value to choose
- B. Historically in clinical research site study coordinator roles have been filled by people with clinical or clinical research experience
- C. It is possible that clerical personnel could be hired by sites because data entry requires little training and use of clerical personnel would reduce burden on sites
- D. Data entry at sites requires study-specific training on how to use the EDC system to enter data and respond to data discrepancies identified by the system
正解：D
解説：
Although clerical staff can technically perform data entry, data entry in clinical research requires study-specific training, particularly in the use of the Electronic Data Capture (EDC) system and understanding data discrepancy resolution procedures.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data Collection) and ICH E6 (R2), individuals responsible for data entry at clinical sites must be qualified by education, training, and experience. This includes understanding how to navigate the EDC system, enter data according to CRF Completion Guidelines, and appropriately respond to queries or system-generated edit checks.
Untrained clerical personnel may inadvertently introduce errors, violate Good Clinical Practice (GCP) standards, or fail to recognize protocol-relevant data. Therefore, the Data Manager must ensure that site users receive study-specific and system training before gaining access to the EDC environment.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 5.2 - Investigator Site Training and Data Entry Requirements ICH E6 (R2) Good Clinical Practice, Section 4.1.5 - Qualified Personnel and Training Requirements FDA 21 CFR Part 11 - User Access and Training Provisions for Electronic Records
質問 # 91
Which statement is true regarding User Acceptance Testing (UAT) in an EDC application?
- A. Data should not be collected in a production environment until UAT is completed
- B. The extent of UAT (i.e., the number of test cases and rules) cannot be risk-based
- C. Every rule should be tested with at least one "pass" and one "fail" scenario
- D. System tools in EDC do not remove the need for UAT
正解：A
解説：
In Electronic Data Capture (EDC) system validation, User Acceptance Testing (UAT) is a mandatory phase that must be completed before data collection begins in the production environment.
According to the GCDMP (Chapter: Database Design, Validation, and Testing) and FDA 21 CFR Part 11, UAT ensures that the EDC system meets all protocol-specific, functional, and regulatory requirements before it is deployed for live use. The goal is to verify that the system performs exactly as intended by simulating real-world user interactions with test data in a validated test environment.
Data collection prior to UAT completion would violate validation requirements and risk noncompliance with ICH E6 (R2) GCP Section 5.5.3, which mandates that all computerized systems be validated and tested before use.
While options A and C describe correct components of testing strategy, the key regulatory requirement is that UAT must be completed and approved before live data entry begins. Option D is incorrect - risk-based UAT is an accepted modern validation approach under both FDA and GAMP5 principles.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Design and Validation, Section 5.3 - User Acceptance Testing FDA 21 CFR Part 11 - Validation of Electronic Systems (Section 11.10(a)) ICH E6 (R2) GCP, Section 5.5.3 - Validation Before Use in Production Environment
質問 # 92
Every database lock should follow documented approval of which stakeholders?
- A. Clinical/Scientific Representative, Biostatistician
- B. Clinical/Scientific Representative, Data Manager, Biostatistician
- C. Clinical/Scientific Representative, Data Manager
- D. Clinical/Scientific Representative, Biostatistician, Programmer
正解：B
解説：
According to the Good Clinical Data Management Practices (GCDMP), the database lock (DBL) process signifies the formal closure of the clinical trial database, ensuring that no further changes can be made to the data before statistical analysis. This process must be documented, controlled, and approved by key study stakeholders to ensure data accuracy, completeness, and readiness for analysis.
The GCDMP specifies that database lock should occur only after all data cleaning, discrepancy resolution, and reconciliation activities are complete. The lock authorization typically requires the approval of the Clinical/Scientific Representative (to confirm clinical completeness), the Data Manager (to confirm data integrity and query closure), and the Biostatistician (to confirm readiness for statistical analysis).
This tri-party approval ensures that the database reflects final, verified data consistent with the clinical protocol, and that the statistical analysis dataset derived from the database is accurate and auditable. The approval process is documented via a Database Lock Authorization Form or Sign-off Log, which becomes part of the permanent trial master file (TMF).
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Lock and Archiving, Section 7.1 - Lock Procedures and Approvals ICH E6 (R2) GCP, Section 5.5.3 - Data Handling and Record Keeping FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Section on Database Closure
質問 # 93
Which of the following scenarios requires a query to be sent to the central lab first when there is a discrepancy between the final lab data transfer and the CRF?
- A. Both the central lab and the CRF data have missing data for a visit
- B. The CRF has data for a visit but the central lab has missing data for the visit
- C. The central lab has data for a visit but the CRF has missing data for the visit
- D. Both the central lab and the CRF have data present for a visit
正解：C
解説：
During data reconciliation between a central laboratory and CRF data, the source of truth is typically the central lab database, as it provides directly measured, vendor-generated results.
When the central lab has data but the CRF does not (option C), the Data Manager must first query the central lab to confirm that the result was transmitted correctly, since discrepancies may stem from data processing or timing issues. Once confirmed, a secondary query may be issued to the site to ensure CRF completion and alignment.
Conversely, if the CRF contains data but the central lab is missing results (option B), the issue is site-level, not vendor-level.
According to the GCDMP (Chapter: External Data Transfers and Reconciliation), priority for querying depends on the authoritative source - for lab data, the central lab is considered the source of record.
Therefore, option C is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: External Data Transfers and Reconciliation, Section 6.1 - Reconciliation of Central Lab and CRF Data ICH E6(R2) GCP, Section 5.5.3 - Source Data Verification and Vendor Reconciliation FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.4 - Data Reconciliation and Traceability
質問 # 94
An organization is using an international data exchange standard and a new version is released. Which of the following should be assessed first?
- A. Existence of backwards compatibility
- B. Content coverage of the new version
- C. Cost of migrating to the new version
- D. Availability of other standards covering the same content
正解：A
解説：
When an updated version of a data exchange standard (such as CDISC SDTM, ADaM, or ODM) is released, the first factor that should be assessed is backwards compatibility. This determines whether the new version can interoperate with or accept data from prior versions without significant reconfiguration or data loss.
According to the Good Clinical Data Management Practices (GCDMP) and CDISC Implementation Guides, assessing backwards compatibility ensures that historical or ongoing study data remain valid and usable within the updated environment. If the new version introduces structural or semantic changes (such as variable name modifications or controlled terminology updates), it could impact mapping, validation, or regulatory submissions.
Once backward compatibility is confirmed, secondary assessments such as content coverage, availability of overlapping standards, and migration cost can be considered. However, ensuring that the new version supports existing infrastructure and data continuity is the first critical step before adoption.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Standards and Data Integration, Section 4.2 - Data Standards Updates and Compatibility Considerations CDISC SDTM Implementation Guide, Section 1.5 - Backward Compatibility and Version Control ICH E6(R2) GCP, Section 5.5 - Data Handling and Standardization
質問 # 95
ACME Intervention Co. is testing a new carotid artery stent in patients with coronary artery disease, in hopes of proving superiority over the current standard of care. After a subject signs consent, the surgeon enrolls the patient and retrieves information on which stent to use, but the surgeon does not share this information with the subject. Yesterday, the surgeon was instructed to use the control stent. Today, the surgeon has completed two surgeries: the first one the surgeon was instructed to use the control stent; the second one the surgeon was instructed to use the test stent. In what type of trial is the surgeon participating?
- A. Single-blind
- B. Open label
- C. Double-blind
- D. Cross-over
正解：A
解説：
This scenario describes a single-blind trial, in which only one party-typically the subject-is unaware of the treatment assignment, while the investigator or surgeon knows which intervention is being administered.
In this case, the surgeon receives instructions on which stent (test or control) to use, meaning they are aware of treatment allocation. However, the subject is blinded to which device is being implanted. This setup minimizes subject bias while maintaining procedural safety since the surgeon must know which product to use.
Double-blind (A): Neither subject nor investigator knows the treatment.
Open-label (B): Both subject and investigator know the treatment.
Cross-over (D): Each subject receives both treatments in different periods.
Thus, the correct answer is C. Single-blind, as only the participant remains blinded in this surgical device trial design.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Clinical Trial Phases and Protocols, Section 3.2 - Study Blinding and Randomization Concepts ICH E6(R2) GCP, Section 1.10 - Definition of Blinding/Masking FDA Guidance for Industry: Design Considerations for Pivotal Clinical Investigations for Medical Devices, Section 5.3 - Blinding in Device Studies
質問 # 96
Which of the following is the best reason for a statistician to review the case report form prior to using it in a study?
- A. To ensure the data from the CRF can be analyzed for safety and efficacy
- B. To ensure the header fields will provide a unique key for each subject
- C. To ensure the variable names conform to statistical programming standards
- D. To ensure the layout will make a logical, useful programming guide
正解：A
解説：
The primary reason a statistician reviews the Case Report Form (CRF) is to ensure that the data being collected will support the planned statistical analyses for both safety and efficacy endpoints.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data Collection), CRF design should always align with the statistical analysis plan (SAP) to ensure that all necessary data elements are collected accurately and in analyzable formats. The statistician verifies that the CRF captures:
All endpoints specified in the protocol
Proper derivation or calculation fields
Timing of assessments
Consistency across visits and forms
Options B, C, and D address secondary or technical design considerations but not the primary analytical purpose. The review ensures that the CRF provides a complete and analyzable dataset for meeting study objectives, regulatory submissions, and statistical integrity.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 4.4 - Role of Statistics in CRF Design ICH E9 - Statistical Principles for Clinical Trials, Section 5.2 - Data Collection and Analysis Alignment FDA Guidance for Industry: E6(R2) GCP, Section 5.1 - Quality Management and Design Input from Stakeholders
質問 # 97
Which information should be communicated by the Data Manager at regular intervals throughout a study?
- A. Serious and unexpected safety events
- B. Site staffing changes
- C. Planned versus actual enrollment
- D. Percent data entered and clean
正解：D
解説：
The Data Manager (DM) plays a critical role in maintaining transparent communication with the clinical study team regarding data quality and study progress. One of the most essential metrics regularly reported by the DM is the percentage of data entered and cleaned.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Communication and Study Reporting), these metrics provide insight into study status, data readiness for interim analysis, and timeline predictability for database lock. Regular communication includes:
Percent of CRFs entered and verified
Percent of queries resolved
Outstanding data issues or missing pages
Other options fall outside the Data Manager's direct responsibility:
A (Enrollment) is typically reported by clinical operations.
B (Staffing changes) are handled by site management.
D (Safety events) are communicated by the safety/pharmacovigilance team.
Thus, option C correctly reflects the Data Manager's responsibility for ongoing study communication.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Communication and Study Reporting, Section 5.3 - Study Metrics and Status Updates ICH E6(R2) GCP, Section 5.1.1 - Communication and Oversight in Quality Management FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.5 - Data Status Reporting
質問 # 98
What are the first logical specifications that need approval when building an efficient EDC database?
- A. Edit Check Logic
- B. eCRF Fields
- C. eCRF Guidelines
- D. Metric Reports
正解：B
解説：
In the EDC database build process, the first logical specifications that require approval are the electronic Case Report Form (eCRF) fields.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Database Design and Build), eCRF field specifications define what data elements are collected, their data types, permitted values, field lengths, and any associated metadata. Approval of these specifications forms the foundation for subsequent design components such as edit check programming, query management rules, and data validation logic.
Edit checks (B) are developed only after fields and structures are finalized.
Metric reports (C) and eCRF guidelines (D) are downstream documentation or tools, not logical specifications required at the build start.
Therefore, option A (eCRF fields) is correct, as their approval marks the first formal milestone in the EDC system development life cycle.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 4.2 - Logical Design and eCRF Field Specifications ICH E6(R2) GCP, Section 5.5.3 - System Design and Validation Documentation FDA 21 CFR Part 11 - System Validation and Documentation Controls
質問 # 99
An asthma study is taking into account local air quality and receives that data from the national weather bureau. Which information is needed to link research subject data to the air-quality readings?
- A. Location, time and subject identifiers
- B. Location and time identifiers
- C. Location, time, subject and site identifiers
- D. Location identifier
正解：B
解説：
When integrating external environmental data such as air quality readings with clinical study data, it is essential to use location and time identifiers to properly align the environmental data with subject-level data.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Management Planning and Study Start-up), external data sources (like national weather or pollution databases) must be merged using common linkage variables that allow synchronization without breaching subject confidentiality. In this case:
Location identifiers (e.g., city, postal code, or region) align the subject's study site or residential area with the environmental dataset.
Time identifiers (e.g., date and time of data collection) ensure that the environmental readings correspond to the same period as the subject's clinical observations.
Including subject identifiers (option C or D) is unnecessary and would pose privacy and data protection risks. Instead, linkage is typically done at the aggregate (site or regional) level, maintaining compliance with HIPAA and GDPR.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Integration and External Data Handling, Section 4.3 - Linking External Data Sources ICH E6 (R2) GCP, Section 5.5.3 - Data Traceability and External Data Management FDA Guidance for Industry: Use of Electronic Health Record Data in Clinical Investigations, Section 5.2 - Linking and Integration Principles
質問 # 100
In a physical therapy study, range of motion is assessed by a physical therapist at each site using a study-provided goniometer. Which is the most appropriate quality control method for the range of motion measurement?
- A. Reviewing data listings for illogical changes in range of motion between visits
- B. Programmed edit checks to detect out-of-range values upon data entry
- C. Independent assessment by a second physical therapist during the visit
- D. Comparison to the measurement from the previous visit
正解：C
解説：
In this scenario, the variable of interest-range of motion (ROM)-is a clinically measured, observer-dependent variable. The accuracy and reliability of such data depend primarily on the precision and consistency of the measurement technique, not merely on data entry validation. Therefore, the most appropriate quality control (QC) method is independent verification of the measurement by a second qualified assessor during the visit (Option D).
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Quality Assurance and Control), quality control procedures must be tailored to the nature of the data. For clinically assessed variables, especially those involving human judgment (e.g., physical measurements, imaging assessments, or subjective scoring), real-time verification by an independent qualified assessor ensures that data are valid and reproducible at the point of collection. This approach directly addresses measurement bias, observer variability, and instrument misuse, which are primary sources of data error in clinical outcome assessments.
Other options, while valuable, address only data consistency or plausibility after collection:
Option A (comparison to previous visit) and Option C (reviewing data listings) are retrospective data reviews, suitable for identifying trends but not preventing measurement error.
Option B (programmed edit checks) detects only extreme or impossible values, not measurement inaccuracies due to technique or observer inconsistency.
The GCDMP and ICH E6 (R2) Good Clinical Practice guidelines emphasize that data quality assurance should begin at the source, through standardized procedures, instrument calibration, and dual assessments for observer-dependent measures. Having an independent second assessor ensures inter-rater reliability and provides direct confirmation that the recorded value reflects an accurate and valid measurement.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 7.4 - Measurement Quality and Verification ICH E6 (R2) Good Clinical Practice, Section 2.13 - Quality Systems and Data Integrity FDA Guidance for Industry: Patient-Reported Outcome Measures and Clinical Outcome Assessment Data, Section 5.3 - Quality Control of Clinician-Assessed Data SCDM GCDMP Chapter: Source Data Verification and Quality Oversight Procedures
質問 # 101
......
認定問題集でClinical Data Management CCDMガイド100%有効な：https://www.goshiken.com/SCDM/CCDM-mondaishu.html
問題集であなたのCCDM Certified Clinical Data Managerは100%一発でパス：https://drive.google.com/open?id=1YI7uyMixxjrYS4ItVcJNzErObgSLn0ca